-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Chemours, Lowers Price Target to $18

Benzinga·11/11/2025 20:57:53
Listen to the news
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $21 to $18.